Saturday, August 30, 2014 4:03:12 PM
Date:August 29, 2014
Source:
DOE/Argonne National Laboratory
Summary:
Researchers have identified one way the Ebola virus dodges the body's antiviral defenses, providing important insight that could lead to new therapies.
Researchers at the Washington University School of Medicine have identified one way the Ebola virus dodges the body's antiviral defenses, providing important insight that could lead to new therapies, in research results published in the journal Cell Host & Microbe.
In work performed at Beamline 19ID at Argonne National Laboratory's Advanced Photon Source, the researchers developed a detailed map of how a non-pathogenic Ebola protein, VP24, binds to a host protein that takes signaling molecules in and out of the cell nucleus.
Their map revealed that the viral protein takes away the host protein's ability to carry an important immune signal into the nucleus. This signal helps activate the immune system's antiviral defenses, and blocking it is believed to contribute significantly to the virus's deadliness.
Story Source:
The above story is based on materials provided by DOE/Argonne National Laboratory. Note: Materials may be edited for content and length.
Journal Reference:
Wei Xu, Megan R. Edwards, Dominika M. Borek, Alicia R. Feagins, Anuradha Mittal, Joshua B. Alinger, Kayla N. Berry, Benjamin Yen, Jennifer Hamilton, Tom J. Brett, Rohit V. Pappu, Daisy W. Leung, Christopher F. Basler, Gaya K. Amarasinghe. Ebola Virus VP24 Targets a Unique NLS Binding Site on Karyopherin Alpha 5 to Selectively Compete with Nuclear Import of Phosphorylated STAT1. Cell Host & Microbe, 2014; 16 (2): 187 DOI: 10.1016/j.chom.2014.07.008
http://dx.doi.org/10.1016/j.chom.2014.07.008
Cite This Page:
MLA APA Chicago
DOE/Argonne National Laboratory. "How Ebola blocks immune system." ScienceDaily. ScienceDaily, 29 August 2014. <www.sciencedaily.com/releases/2014/08/140829135459.htm>.
http://www.sciencedaily.com/releases/2014/08/140829135459.htm
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM